This invention describes new hydrated and anhydrous polymorphs of 2-0-fucosyllactose (2FL): Polymorph A 2FL-3/2H.sub.2O, Polymorph B 2TL-5/2 H.sub.2O and anhydrous Polymorph C. There is also a description of the methods for obtaining them, and of a new method for preparing Polymorph I already known in the literature. ##STR00001##

This invention describes new hydrated and anhydrous polymorphs of 2-0-fucosyllactose (2FL): Polymorph A 2FL-3/2H.sub.2O, Polymorph B 2TL-5/2 H.sub.2O and anhydrous Polymorph C. There is also a description of the methods for obtaining them, and of a new method for preparing Polymorph I already known in the literature. ##STR00001##

The invention pertains to a process for simultaneous producing an infant formula product and an acidic dairy product from defatted animal milk, comprising (a) processing the milk into a casein stream, a whey protein stream and a lactose stream, by: (i) subjecting the defatted animal milk to a filtration step over a microfiltration membrane capable of retaining bacteria and permeating milk proteins, to provide a debacterialized milk as permeate; (ii) subjecting the permeate originating from step (i) to a filtration step over a microfiltration membrane capable of retaining casein and permeating whey proteins, to provide a casein stream as retentate and a permeate comprising whey protein; (iii) fractionating the permeate originating from step (ii) into a whey protein stream and a lactose stream; (b) combining part of the casein stream, at least part of the whey protein stream originating from step (a) and a lactose source to obtain a recombined stream, wherein the lactose source comprises acid whey; (c) using the recombined stream originating from step (b) in the manufacture of the infant formula product; (d) using part of the casein stream originating from step (a) in the manufacture of the acidic dairy product. The invention further concerns the infant formula product obtainable by step (c) of the process according to the invention, and to the acidic dairy product obtainable by step (d) of the process according to the invention.

The present invention relates to a complementary nutritional composition characterized by a low glycemic load and/or index and/or comprising an ingredient characterized by a low glycemic index for use in treatment, prevention and/or reducing the risk of a metabolic syndrome disorder appearing later in life.

The present invention relates to a complementary nutritional composition characterized by a low glycemic load and/or index and/or comprising an ingredient characterized by a low glycemic index for use in treatment, prevention and/or reducing the risk of a metabolic syndrome disorder appearing later in life.

The present invention relates to a food composition and a cosmetic composition for improving skin beauty, which include galactooligosaccharide and have an ability to increase a skin water holding capacity, an ability to suppress transepidermal water loss, an ability to alleviate wrinkles, and an ability to alleviate erythema.

The present invention relates to a nutritional composition comprising at least one fucosylated oligosaccharide for use in an infant or a young child for reducing and/or preventing later in life excessive fat mass accumulation and/or a health disorder related to excessive fat mass accumulation, wherein said fucosylated oligosaccharide has at least one fucose group attached by an alpha 1,3 linkage, at least one fucose group attached by an alpha 1,4 linkage, or combinations thereof. The invention also relates to nutritional composition for use to promote healthy growth.

Provided are a composition for inhibiting immune cell proliferation, including sialyllactose or a derivative thereof as an active ingredient, and a method of inhibiting immune cell proliferation, wherein the composition and the method may decrease expression of chemokines, decrease expression of pro-inflammatory cytokines, decrease production of inflammatory mediators, decrease expression of COX2, and decrease production of PEG.sub.2, and therefore, may be useful for the prevention or treatment of atopic dermatitis or arthritis.

Provided are a composition for inhibiting immune cell proliferation, including sialyllactose or a derivative thereof as an active ingredient, and a method of inhibiting immune cell proliferation, wherein the composition and the method may decrease expression of chemokines, decrease expression of pro-inflammatory cytokines, decrease production of inflammatory mediators, decrease expression of COX2, and decrease production of PEG.sub.2, and therefore, may be useful for the prevention or treatment of atopic dermatitis or arthritis.

Disclosed is a frozen confection comprising freezing point depressants in an amount of from 25 to 35% by weight of the frozen confection, wherein the number average molecular weight <M>.sub.n of the freezing point depressants is from 200 to 250 g mol.sup.1, and wherein the freezing point depressants comprise erythritol in an amount of from 0.25 to 5 7% by weight of the frozen confection.